Executive Vice President and Chief Scientific Officer, Immunogen
Dr. Gregory received his Ph.D. in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology in Shrewsbury MA. In 1989 he joined Genzyme Corporation, where he was responsible for discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) protein and to determine the molecular defect caused by the most common mutation of CFTR. In 2003 Richard became Senior Vice President and Head of Research for Genzyme Corporation where he was responsible for early R&D, from discovery to development, in all therapeutic areas at Genzyme. In 2011, following the acquisition of Genzyme by Sanofi, Richard was appointed Head of the Sanofi Genzyme R&D Center, overseeing R&D in rare diseases, multiple sclerosis, immune disorders and tissue protection/regenerative medicine. In January of 2015 Dr. Gregory joined ImmunoGen, where he oversees research leading to new antibody based therapeutics to address the unmet needs of patients with cancer. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.